ONS vs. CGEM, LENZ, AUTL, VECT, HUMA, TECX, CRGX, DNA, TRML, and OPT
Should you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Autolus Therapeutics (AUTL), VectivBio (VECT), Humacyte (HUMA), Tectonic Therapeutic (TECX), CARGO Therapeutics (CRGX), Ginkgo Bioworks (DNA), Tourmaline Bio (TRML), and Opthea (OPT). These companies are all part of the "medical" sector.
Oncobiologics vs.
Oncobiologics (NASDAQ:ONS) and Cullinan Therapeutics (NASDAQ:CGEM) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.
Cullinan Therapeutics has a net margin of 0.00% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Cullinan Therapeutics' return on equity.
Oncobiologics received 132 more outperform votes than Cullinan Therapeutics when rated by MarketBeat users. However, 82.35% of users gave Cullinan Therapeutics an outperform vote while only 63.74% of users gave Oncobiologics an outperform vote.
7.2% of Oncobiologics shares are held by institutional investors. Comparatively, 86.3% of Cullinan Therapeutics shares are held by institutional investors. 11.5% of Oncobiologics shares are held by insiders. Comparatively, 6.1% of Cullinan Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Oncobiologics has a beta of -0.27, indicating that its share price is 127% less volatile than the S&P 500. Comparatively, Cullinan Therapeutics has a beta of -0.14, indicating that its share price is 114% less volatile than the S&P 500.
Cullinan Therapeutics has a consensus price target of $31.67, indicating a potential upside of 203.90%. Given Cullinan Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cullinan Therapeutics is more favorable than Oncobiologics.
Oncobiologics has higher revenue and earnings than Cullinan Therapeutics.
In the previous week, Cullinan Therapeutics had 2 more articles in the media than Oncobiologics. MarketBeat recorded 2 mentions for Cullinan Therapeutics and 0 mentions for Oncobiologics. Cullinan Therapeutics' average media sentiment score of 0.49 beat Oncobiologics' score of 0.00 indicating that Cullinan Therapeutics is being referred to more favorably in the news media.
Summary
Cullinan Therapeutics beats Oncobiologics on 10 of the 15 factors compared between the two stocks.
Get Oncobiologics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncobiologics Competitors List
Related Companies and Tools
This page (NASDAQ:ONS) was last updated on 1/22/2025 by MarketBeat.com Staff
Free ONS Stock Alerts